Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
SASY | Paris | EUR | Real-time | |
SANp | BATS Europe | EUR | Delayed | |
SNY | NASDAQ | USD | Real-time | |
0O59 | London | EUR | Real-time | |
SNYN | Mexico | MXN | Delayed | |
SANF | Milan | EUR | Real-time | |
SASY | TradeGate | EUR | Delayed | |
SASY | Frankfurt | EUR | Delayed | |
SASY | Xetra | EUR | Delayed | |
SASY | Vienna | EUR | Real-time |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Strong Sell | Sell | Buy | Buy | Buy |
Technical Indicators | Neutral | Strong Sell | Neutral | Strong Buy | Strong Buy |
Summary | Sell | Strong Sell | Neutral | Strong Buy | Strong Buy |
Filter Table By:
Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
---|---|---|---|---|---|
Completed Patterns | |||||
Dragonfly Doji | 30 | 1 | Dec 24, 2021 12:00 | ||
Three Outside Up | 1W | 2 | Dec 12, 2021 | ||
Engulfing Bearish | 1M | 3 | Sep 21 | ||
Bullish Engulfing | 1W | 3 | Dec 05, 2021 | ||
Doji Star Bearish | 1M | 7 | May 21 |
Exchange | Last | Bid | Ask | Volume | Change % | Currency | Time | ||
---|---|---|---|---|---|---|---|---|---|
Paris | 90.96 | 0.00 | 0.00 | 1,839,942 | -0.87% | EUR | |||
BATS Europe | 91.14 | 90.29 | 0.00 | 0 | 0.00% | EUR | |||
NASDAQ | 48.60 | 48.50 | 49.70 | 2,414,975 | -1.90% | USD | |||
London | 91.10 | 89.69 | 92.42 | 1,168,199 | -0.85% | EUR | |||
Mexico | 804.15 | 720.11 | 850.00 | 0 | 0.00% | MXN | |||
Milan | 91.09 | 0.00 | 0.00 | 863 | +0.10% | EUR | |||
TradeGate | 89.79 | 89.68 | 89.81 | 0 | 0.00% | EUR | |||
Frankfurt | 91.43 | 89.66 | 89.83 | 0 | 0.00% | EUR | |||
Xetra | 91.170 | 91.090 | 92.050 | 1,122 | -0.90% | EUR | |||
Vienna | 89.10 | 88.98 | 89.38 | 0 | +0.00% | EUR |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
IAG | 176.75 | 177.70 | 170.95 | +5.25 | +3.06% | 34.56M | 28/03 | ||
Rolls-Royce Holdings | 426.70 | 430.50 | 411.40 | +4.70 | +1.11% | 16.81M | 28/03 | ||
Lloyds Banking | 51.76 | 52.54 | 51.57 | +0.09 | +0.17% | 157.24M | 28/03 | ||
Barclays | 183.20 | 185.74 | 182.82 | +1.68 | +0.93% | 48.73M | 28/03 | ||
Avacta Group | 49.75 | 50.00 | 48.40 | +0.75 | +1.53% | 3.37M | 28/03 | ||
Vodafone Group PLC | 70.460 | 70.720 | 69.700 | +1.040 | +1.50% | 65.30M | 28/03 | ||
JD Sports Fashion | 134.50 | 136.75 | 114.86 | +18.20 | +15.65% | 61.63M | 28/03 | ||
BP | 495.70 | 498.75 | 493.30 | +2.90 | +0.59% | 35.58M | 28/03 | ||
EasyJet | 570.80 | 572.80 | 556.40 | +13.20 | +2.37% | 4.63M | 28/03 | ||
Greatland Gold | 6.200 | 6.600 | 6.100 | -0.270 | -4.17% | 17.37M | 28/03 |
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Read MoreAre you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review